{"id":1016642,"date":"2026-11-03T07:48:29","date_gmt":"2026-11-03T12:48:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/"},"modified":"2026-11-03T07:48:29","modified_gmt":"2026-11-03T12:48:29","slug":"cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/","title":{"rendered":"Cardiff Oncology to\u00a0Participate in the\u00a0UBS Global Biopharma Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Nov.  03, 2026  (GLOBE NEWSWIRE) &#8212; Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1&#215;1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026.<\/p>\n<p>Details of the presentation can be found below.<\/p>\n<p align=\"justify\">\n        <strong>Format:\u00a0<\/strong>Fireside Chat<br \/><strong>Presenter:<\/strong>\u202fMani\u202fMohindru, PhD\u202f(President and CEO)<br \/><strong>Date:<\/strong>\u00a0November 16, 2026<br \/><strong>Time:<\/strong><strong>\u00a0<\/strong>2:40 PM\u00a0GMT<\/p>\n<p align=\"justify\">Interested parties can\u00a0register for and\u00a0access the live webcast for the conference by visiting the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JIUbSd_lXmADvnEwipVNiYPXCFtdXB3SrESa-GNcWpybIaBcX_UzJnqrqh9jneUfL04L4GpSFNyO2kc2Zl1AeSilp4F6RiLlEKZaKrzE4R5c2lqUIvpoPSatx-6S9G1v\" rel=\"nofollow\" target=\"_blank\">Events<\/a>\u201d section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Cardiff<\/strong><br \/>\n        <strong>\u00a0<\/strong><br \/>\n        <strong>Oncology, Inc.<\/strong><br \/>\n        <br \/>Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Cardiff\u2019s lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated mCRC, addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.<\/p>\n<p align=\"justify\">For more information, please visit https:\/\/www.cardiffoncology.com.<\/p>\n<p align=\"justify\">\n        <strong>Investor<\/strong><br \/>\n        <strong>\u202f<\/strong><br \/>\n        <strong>Contact:<\/strong>\u202f<br \/>Candice Masse\u202f<br \/>Astr\u202fPartners\u202f<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mYyfFr5dVtDVnc1IU8Viz6bjvLuRmWoE4mDGrq_Uf84ppp6fD_DnxDZGDEGa0lzMRofrzOcKBCPyqVbK2TpKNOKo5JdTH_YZWgRkMGl4ZG7LmjGAwl87YBPuGU556BJd\" rel=\"nofollow\" target=\"_blank\">candice.masse@astrpartners.com<\/a>\u202f<\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Amy Bonanno<br \/>Lyra Strategic Advisory<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ETUhss-O6Bw0X7SbSoG3BVT2iLV1NiIzFwbSzOEl_XH7RL8CkTNT5JKJoHX-i4M31eQhjzo2JxxyEBRQfpGdyK0LQekRhyMLFA1nbIiB1ar9-2Irb_w8kCiT0Go56ecC\" rel=\"nofollow\" target=\"_blank\">abonanno@lyraadvisory.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NDQ0MCM3OTE5NjQ5IzIyNTc1MDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDYyNDdlZTYtYTlmMS00NGI0LTlmNjEtZTA1MGFlMzMwNmY0LTEyNjkwNTItMjAyNi0xMS0wMy1lbg==\/tiny\/Cardiff-Oncology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) &#8212; Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1&#215;1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026. Details of the presentation can be found below. Format:\u00a0Fireside ChatPresenter:\u202fMani\u202fMohindru, PhD\u202f(President and CEO)Date:\u00a0November 16, 2026Time:\u00a02:40 PM\u00a0GMT Interested parties can\u00a0register for and\u00a0access the live webcast for the conference by visiting the \u201cEvents\u201d section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation. About\u00a0Cardiff \u00a0 Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cardiff Oncology to\u00a0Participate in the\u00a0UBS Global Biopharma Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1016642","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cardiff Oncology to\u00a0Participate in the\u00a0UBS Global Biopharma Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardiff Oncology to\u00a0Participate in the\u00a0UBS Global Biopharma Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) &#8212; Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1&#215;1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026. Details of the presentation can be found below. Format:\u00a0Fireside ChatPresenter:\u202fMani\u202fMohindru, PhD\u202f(President and CEO)Date:\u00a0November 16, 2026Time:\u00a02:40 PM\u00a0GMT Interested parties can\u00a0register for and\u00a0access the live webcast for the conference by visiting the \u201cEvents\u201d section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation. About\u00a0Cardiff \u00a0 Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, &hellip; Continue reading &quot;Cardiff Oncology to\u00a0Participate in the\u00a0UBS Global Biopharma Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-03T12:48:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NDQ0MCM3OTE5NjQ5IzIyNTc1MDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cardiff Oncology to\u00a0Participate in the\u00a0UBS Global Biopharma Conference\",\"datePublished\":\"2026-11-03T12:48:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\\\/\"},\"wordCount\":247,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NDQ0MCM3OTE5NjQ5IzIyNTc1MDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\\\/\",\"name\":\"Cardiff Oncology to\u00a0Participate in the\u00a0UBS Global Biopharma Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NDQ0MCM3OTE5NjQ5IzIyNTc1MDM=\",\"datePublished\":\"2026-11-03T12:48:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NDQ0MCM3OTE5NjQ5IzIyNTc1MDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NDQ0MCM3OTE5NjQ5IzIyNTc1MDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cardiff Oncology to\u00a0Participate in the\u00a0UBS Global Biopharma Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cardiff Oncology to\u00a0Participate in the\u00a0UBS Global Biopharma Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/","og_locale":"en_US","og_type":"article","og_title":"Cardiff Oncology to\u00a0Participate in the\u00a0UBS Global Biopharma Conference - Market Newsdesk","og_description":"SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) &#8212; Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1&#215;1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026. Details of the presentation can be found below. Format:\u00a0Fireside ChatPresenter:\u202fMani\u202fMohindru, PhD\u202f(President and CEO)Date:\u00a0November 16, 2026Time:\u00a02:40 PM\u00a0GMT Interested parties can\u00a0register for and\u00a0access the live webcast for the conference by visiting the \u201cEvents\u201d section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation. About\u00a0Cardiff \u00a0 Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, &hellip; Continue reading \"Cardiff Oncology to\u00a0Participate in the\u00a0UBS Global Biopharma Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-03T12:48:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NDQ0MCM3OTE5NjQ5IzIyNTc1MDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cardiff Oncology to\u00a0Participate in the\u00a0UBS Global Biopharma Conference","datePublished":"2026-11-03T12:48:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/"},"wordCount":247,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NDQ0MCM3OTE5NjQ5IzIyNTc1MDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/","name":"Cardiff Oncology to\u00a0Participate in the\u00a0UBS Global Biopharma Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NDQ0MCM3OTE5NjQ5IzIyNTc1MDM=","datePublished":"2026-11-03T12:48:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NDQ0MCM3OTE5NjQ5IzIyNTc1MDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NDQ0MCM3OTE5NjQ5IzIyNTc1MDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-the-ubs-global-biopharma-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cardiff Oncology to\u00a0Participate in the\u00a0UBS Global Biopharma Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1016642"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016642\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1016642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1016642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1016642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}